Shares of Intrexon Corp (NYSE:XON) ended Friday session in red amid volatile trading. The shares closed down -1.89 points or -6.93% at $25.40 with 1,873,187 shares getting traded. Post opening the session at $26.88, the shares hit an intraday low of $25.38 and an intraday high of $27.31 and the price vacillated in this range throughout the day. The company has a market cap of $2.80 billion and the numbers of outstanding shares have been calculated to be 118.33 million shares.
Intrexon Corp (XON) on Sept. 7, 2016 reported a bipartisan coalition of 61 Florida House members led by Speaker-designate Richard Corcoran and Democratic Leader-designate Janet Cruz have issued a letter urging the U.S. Federal Government to take proactive steps including Emergency Use Authorization (EUA) to allow Florida’s state and local governments to use Oxitec’s genetically engineered Friendly™ Aedes to suppress Aedes aegypti mosquitoes that transmit Zika, chikungunya, dengue and other dangerous viruses to humans.
The letter from Mr. Corcoran, Ms. Cruz, and other House representatives to the U.S. Department of Health and Human Services (HHS) Secretary Sylvia Matthews Burwell and U.S. Food and Drug Administration (FDA) Commissioner Robert M. Califf, MD, expresses concerns about delaying Florida’s access to Oxitec’s Friendly™ Aedes technology, stating that such a delay “presents an unnecessary health risk” to the people of Florida, which could result in “the loss of human life”. The letter urges HHS and FDA to grant an EUA under their applicable authorities to make the Oxitec technology “immediately available in any Florida area where Zika is being transmitted or likely to be transmitted”, and it also notes that this authority has been used ten times to make Zika diagnostic tests publicly available.
Hadyn Parry, CEO of Oxitec stated, “We are confident the FDA, HHS and other government agencies will do everything within their power to ensure the safety of the American people, including making available novel vector control technologies, such as our Friendly™ Aedes solution, as appropriate. If an EUA or another method allows for our Friendly™ Aedes solution to be deployed, we’re prepared to work with federal, state and local health officials to help all communities that require it in order to address this public health emergency.”
Shares of ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) ended Friday session in red amid volatile trading. The shares closed down -0.38 points or -7.14% at $4.94 with 1.85 million shares getting traded. Post opening the session at $5.21, the shares hit an intraday low of $4.92 and an intraday high of $5.29 and the price vacillated in this range throughout the day. The company has a market cap of $604.28 million and the numbers of outstanding shares have been calculated to be 131.73 million shares.
ZIOPHARM Oncology Inc. (ZIOP) on Aug. 09, 2016 announced financial results for the second quarter ended June 30, 2016, and provided an update on the Company’s recent activities.
“ZIOPHARM had a very productive first half, with the achievement of pipeline and corporate milestones across the breath of our portfolio and the advancement of our goal to position the company at the forefront of those harnessing the immune system to target cancer,” said Laurence Cooper, M.D., Ph.D., Chief Executive Officer of ZIOPHARM Oncology. “Central to this effort, we were pleased to have amended the terms of our collaboration with Intrexon to facilitate the commercialization of our immunotherapy assets. The benefit of this new structure is expected to be first realized with our gene therapy Ad-RTS-hIL-12 + veledimex program, which remains on track to move into a registrational trial in advanced glioblastoma in 2017.”
Dr. Cooper added: “As we progress through the remainder of 2016, we will continue to work with our collaborators, including Intrexon Corporation and the MD Anderson Cancer Center, to advance new therapies into the clinic. We look forward in 2016 to seeing six clinical trials exploring immuno-oncology approaches and combinations, in addition to preclinical projects advancing towards the clinic. As these programs mature, we expect to see proof-of-concept clinical data that will drive value for all of our stakeholders.”